Dianthus Therapeutics Targets Q2 2026 CIDP Phase 3 Readout, Expands Preclinical Pipeline
Dianthus Therapeutics forecasts an interim readout for its chronic inflammatory demyelinating polyneuropathy Phase 3 trial in Q2 2026 after completing patient enrollment by March. The company plans to advance two preclinical autoimmune neurology programs into IND-enabling studies, targeting IND submissions by Q4 2026.
1. Conference Update
During its conference presentation, Dianthus Therapeutics outlined expectations for a Q2 2026 interim readout in its chronic inflammatory demyelinating polyneuropathy Phase 3 trial, noting that full patient enrollment is set to conclude by March 2026 and top-line data will inform potential regulatory discussions.
2. Pipeline Expansion Plans
In addition to its CIDP program, management unveiled plans to advance two preclinical antibody candidates targeting autoimmune neurology indications into IND-enabling studies, aiming to file IND applications by Q4 2026 and broaden its clinical pipeline beyond neuromuscular disorders.